Prostatype Genomics AB (OSTO:PROGEN) Cash Conversion Cycle: 61.36 (As of Dec. 2025)

Prostatype Genomics AB  (OSTO:PROGEN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Prostatype Genomics AB Cash Conversion Cycle Related Terms

The historical data trend for Prostatype Genomics AB's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Cash Conversion Cycle Chart

Prostatype Genomics AB Semi-Annual Data
	Jun18	Jun19	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Cash Conversion Cycle	Get a 7-Day Free Trial								84.42	338.02	93.42	31.90	61.36

OSTO:PROGEN vs TMO, DHR, IDXX: Cash Conversion Cycle Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB Cash Conversion Cycle vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Cash Conversion Cycle falls into.

Prostatype Genomics AB Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Prostatype Genomics AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Prostatype Genomics AB's Cash Conversion Cycle for the quarter that ended in Dec. 2025 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Business Description